Detalhe da pesquisa
1.
MITO END-3: Efficacy of Avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapy.
Ann Oncol
; 2024 May 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38704093
2.
ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease.
Ann Oncol
; 35(3): 248-266, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38307807
3.
Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial.
Ann Oncol
; 34(8): 681-692, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37211045
4.
Randomized phase II BGOG/ENGOT-cx1 study of paclitaxel-carboplatin with or without nintedanib in first-line recurrent or advanced cervical cancer.
Gynecol Oncol
; 174: 80-88, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37167896
5.
Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial.
Ann Oncol
; 33(10): 1021-1028, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35772665
6.
The forefront of ovarian cancer therapy: update on PARP inhibitors.
Ann Oncol
; 31(9): 1148-1159, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32569725
7.
ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease.
Ann Oncol
; 30(5): 672-705, 2019 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31046081
8.
Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study.
Ann Oncol
; 30(7): 1080-1087, 2019 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31046082
9.
Conservative surgery in stage I adult type granulosa cells tumors of the ovary: Results from the MITO-9 study.
Gynecol Oncol
; 154(2): 323-327, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31189500
10.
Carboplatin-paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 - A randomized phase II trial.
Gynecol Oncol
; 155(3): 406-412, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31677820
11.
Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer.
Gynecol Oncol
; 155(2): 186-191, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31519320
12.
ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease.
Int J Gynecol Cancer
; 2019 05 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31048403
13.
Latest clinical evidence and further development of PARP inhibitors in ovarian cancer.
Ann Oncol
; 29(6): 1366-1376, 2018 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29750420
14.
Quality-of-life analysis of the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study comparing platinum-based versus non-platinum-based chemotherapy in patients with partially platinum-sensitive recurrent ovarian cancer.
Ann Oncol
; 29(5): 1189-1194, 2018 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29462248
15.
Combined BRAFV600E analysis and 99mTc-MIBI scintigraphy can be a useful diagnostic tool in differentiated thyroid cancer patients with incomplete bio-chemical response to first radioiodine therapy (RAIT): a pilot investigation.
J Endocrinol Invest
; 41(11): 1283-1288, 2018 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-29549631
16.
Treatment of recurrent ovarian cancer.
Ann Oncol
; 28(suppl_8): viii51-viii56, 2017 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29232464
17.
The role of staging and adjuvant chemotherapy in stage I malignant ovarian germ cell tumors (MOGTs): the MITO-9 study.
Ann Oncol
; 28(2): 333-338, 2017 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27803008
18.
Cisplatin can be safely administered to ovarian cancer patients with hypersensitivity to carboplatin.
Gynecol Oncol
; 144(1): 72-76, 2017 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-28094039
19.
Corrigendum to 'The forefront of ovarian cancer therapy: update on PARP inhibitors': [Annals of Oncology 31 (2020) 1148-1159].
Ann Oncol
; 32(8): 1066-1067, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-34090767
20.
Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trial.
Ann Oncol
; 27(3): 487-93, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26681678